Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: A randomized trial

European Heart Journal

Volumn 35, Issue 46, 2014, Pages 3277-3286

  Tardif, Jean Claude ^a   Ballantyne, Christie M ^b   Barter, Philip ^c   Dasseux, Jean Louis ^d   Fayad, Zahi A ^e   Guertin, Marie Claude ^a   Kastelein, John J P ^f   Keyserling, Constance ^d   Klepp, Heather ^d   Koenig, Wolfgang ^g   L'Allier, Philippe L ^a   Lespérance, Jacques ^a   Lüscher, Thomas F ^h   Paolini, John F ^d   Tawakol, Ahmed ⁱ   Waters, David D ^j  

^a MONTREAL HEART INSTITUTE   (Canada)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d Cerenis Therapeutics   (France)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g UNIVERSITY HOSPITAL ULM   (Germany)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Atherosclerosis; Clinical trial; Coronary disease; High density lipoproteins

Indexed keywords

CARDIOVASCULAR AGENT; CER 001; GLYCERYL TRINITRATE; PLACEBO; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; APOLIPOPROTEIN A1; CER-001; PHOSPHOLIPID;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROMA; CANADA; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; FEMALE; FRANCE; HUMAN; INTENTION TO TREAT ANALYSIS; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; NAUSEA; NETHERLANDS; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; ACUTE CORONARY SYNDROME; AGED; CLINICAL TRIAL; CORONARY ARTERY DISEASE; ECHOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; RADIOGRAPHY; TREATMENT OUTCOME; VERY ELDERLY;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN A-I; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PHOSPHOLIPIDS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84922150195     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu171     Document Type: Article

References (25)

1. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators: intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
2. US Burden of Disease Collaborators. The State of US Health, 1990-2010. JAMA 2013; 310: 591-608.
3. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 2000; 86: 19L-22L.
4. Mora S, Glynn RJ, Ridker PM. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation 2013; 128: 1189-1197.
5. Silbernagel G, Schöttker B, Appelbaum S, Scharnagl H, Kleber ME, Grammer TB, Ritsch A, Mons U, Holleczek B, Goliasch G, Niessner A, Boehm BO, Schnabel RB, Brenner H, Blankenberg S, Landmesser U, März W. High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. Eur Heart J 2013; 34: 3563-3571.
6. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-2267.
7. HPS-2 Thrive Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34: 1279-1291.
8. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-2122.
9. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS. dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367: 2089-2099.
10. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. JAMA 2003; 290: 2292-2300.
11. Tardif JC, Grégoire J, LAllier PL, Ibrahim R, Lespérance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodés-Cabau J. Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007; 297: 1675-1682.
12. Waksman R, Torguson R, Kent KM, Pichard AD, Suddath WO, Satler LF, Martin BD, Perlman TJ, Maltais JA, Weissman NJ, Fitzgerald PJ, Brewer Jr. H.B. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 2010; 55: 2727-2735.
13. Keyserling CH, Hunt TL, Klepp HM, Scott RA, Barbaras R, Schwenderman A, Lalwani N, Dasseux JL. CER-001, a synthetic HDL-mimetic, safely mobilizes cholesterol in healthy dyslipidemic volunteers. Circulation 2011; 124: A15525 (abstract
14. Tardif JC, Grégoire J, Lespérance J, Lambert J, LAllier PL, Rodés J, Anderson T, Blue JW, Imus J, Heinonen T. Design features of the avasimibe and progression of coronary lesions assessed by intravascular ultrasound (A-PLUS) clinical trial. Am Heart J 2002; 144: 589-596.
15. Tardif JC, Grégoire J, LAllier PL, Anderson TJ, Bertrand O, Reeves F, Title LM, Alfonso F, Schampaert E, Hassan A, McLain R, Pressler ML, Ibrahim R, Lespérance J, Blue J, Heinonen T, Rodés-Cabau J. Avasimibe and Progression of Lesions on UltraSound (A-PLUS) Investigators. Effects of the acyl coenzyme A: cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 2004; 110: 3372-3377.
16. Tardif JC, Grégoire J, Schwartz L, Title L, Laramée L, Reeves F, Lespérance J, Bourassa MG, LAllier PL, Glass M, Lambert J, Guertin MC. Canadian Antioxidant Restenosis Trial (CART-1) Investigators. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 2003; 107: 552-558.
17. Berry C, LAllier PL, Grégoire J, Lespérance J, Levesque S, Ibrahim R, Tardif JC. Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression. Circulation 2007; 115: 1851-1857.
18. Côté G, Tardif JC, Lespérance J, Lambert J, Bourassa M, Bonan R, Gosselin G, Joyal M, Tanguay JF, Nattel S, Gallo R, Crépeau J. Effects of probucol on vascular remodeling after coronary angioplasty. Circulation 1999; 99: 30-35.
19. Mintz GS, Garcia-Garcia HM, Nicholls SJ, Weissman NJ, Tardif JC, Serruys PW. Clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound regression/progression studies. EuroIntervention 2011; 6: 1123-1130.
20. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lespérance J. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994; 89: 959-968.
21. Tardif JC, Cöté G, Lespérance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, de Guise P. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997; 337: 365-372.
22. Solymoss BC, Bourassa MG, Campeau L, Sniderman A, Marcil M, Lespérance J, Lévesque S, Varga S. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol 2004; 93: 159-164.
23. Barter PJ, Baker PW, Rye KA. Effect of high-density lipoprotein on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol 2002; 13: 285-288.
24. Riwanto M, Rohrer L, Roschitzki B, Besler C, Mocharla P, Mueller M, Perisa D, Heinrich K, Altwegg L, von Eckardstein A, Lüscher TF, Landmesser U. Altered activation of endothelial anti-And proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoproteinproteome remodeling. Circulation 2013; 127: 891-904.
25. Alam K, Meidell RS, Spady DK. Effect of Up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice. J Biol Chem 2001; 276: 15641-15649.